跳到主要內容

研究成果

2024年論文發表

  1. Bonaccorsi-Riani E, Ghinolfi D, Czigany Z, Dondossola D, Emamaullee J, Yuksel M, Boteon YL, Al-Adra D, Ho CM, Abdelrahim M, Pang L, Barbas A, Meier R, MacParland S, Sayed BA, Pavan-Guimaraes J, Brüggenwirth IMA, Zarrinpar A, Mas VR, Selzner M, Martins PN, Bhat M. What is hot and new in basic and translational science in liver transplantation in 2023? - Report of the Basic and Translational Research Committee of the International Liver Transplantation Society. Transplantation. 2024 May 1;108(5):1043-1052.
  2. Chang A, Jeng YM, Ho CM, Lee PH. Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination. NPJ Vaccines. 2024 Apr 8;9(1):75.
  3. Chang CW, Hsu WF, Tseng KC, Chen CY, Cheng PN, Hung CH, Lo CC, Bair MJ, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Lin CL, Wang CC, Yang SS, Mo LR, Chen GY, Chang CC, Wang SJ, Huang CS, Hsieh TY, Lin CW, Lee TH, Chong LW, Huang CW, Chang SN, Tsai MC, Hsu SJ, Kao JH, Liu CJ, Liu CH, Lin HC, Tsai PC, Yeh ML, Huang CF, Dai CY, Chuang WL, Yu ML, Peng CY. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan. Dig Dis Sci. 2024 Sep;69(9):3501-3512.
  4. Chang HC, Su TH, Huang YT, Hong CM, Sheng WH, Hsueh PR, Kao JH. Liver dysfunction and clinical outcomes of unvaccinated COVID-19 patients with and without chronic hepatitis B. J Microbiol Immunol Infect. 2024 Feb;57(1):55-63.
  5. Chang KC, Chang MH, Chen HL, Cheng FW, Wu JF, Su WJ, Hsu HY, Ni YH. Survey of hepatitis B virus infection status after 35 years of universal vaccination implementation in Taiwan. Liver Int. 2024 Aug;44(8):2054-62.
  6. Chang KC, Su TH, Kao JH. Reply on "Tenofovir is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus-related Hepatocellular Carcinoma". Clin Gastroenterol Hepatol. 2024 Aug 27:S1542-3565(24)00794-8. (Corresponding author)
  7. Chang KC, Su TH, Liao SH, Tseng TC, Huang SC, Hsu SJ, Hong CM, Liu CH, Yang HC, Liu CJ, Kao JH. Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy J Formos Med Assoc. 2024 Aug;123(8):891-898. 
  8. Chang LK, Yang SM, Chien N, Chang CC, Fang HY, Liu MC, Wang KL, Lin WC, Lin FCF, Chuang CY, Hsu PK, Huang TW, Chen CK, Chang YC, Huang KW. 2024 multidisciplinary consensus on image-guided lung tumor ablation from the Taiwan Academy of Tumor Ablation. Thorac Cancer. 2024 Jul;15(20):1607-1613.
  9. Chang SH, Su TH, Ling ZM, Lee MH, Liu CJ, Chen PJ, Yang HC, Liu CH, Chen CL, Tseng TC, Chen CH, Lee HS, Chen CJ, Kao JH. Fibrosis-4 index stratifies risks of hepatocellular carcinoma in patients with chronic hepatitis C. J Formos Med Assoc. 2024 Nov;123(11):1154-1160.
  10. Chang YP, Huang CB, Kao JH, Su TH, Huang SC, Tseng TC, Chen PJ, Liu CJ, Liu CH. Factors associated with pre-treatment hyperferritinemia in patients with chronic hepatitis C virus infection. Sci Rep. 2024 Aug 19;14(1):19219.
  11. Chang YP, Huang CB, Su TH, Liu CJ, Tseng TC, Huang SC, Chen PJ, Kao JH, Liu CH. Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping. J Med Virol. 2024 May;96(5):e29686.
  12. Chang YP, Liu CH, Huang CB, Lee JY, Liu CJ, Su TH, Huang SC, Tseng TC, Chen PJ, Kao JH. Serum Mac-2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus. J Gastroenterol Hepatol. 2024 Nov;39(11):2439-2446.
  13. Chen CL, Huang FF, Lin HF, Wu CC, Ni YH, Lin YC. Tat-Beclin-1 Peptide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Enhancing Hepatic Autophagy. Int J Mol Sci. 2024 Nov 18;25(22):12372.
  14. Chen CL, Tseng TC, Liu CJ, Kao JH, Chen PJ, Yang WS. Serum RNase L levels in patients with chronic hepatitis B virus infection. Hepatol Res. 2024 Mar;54(3):244-251
  15. Chen HL, Jourdain G. Prevention of HBV infection. Clin Liver Dis (Hoboken). 2024 Jun;23:e0194.
  16. Chen HL, Lee CN, Chang CH, Lai MW, Tsai MC, Mu SC, Liu CJ, Shih JC, Wen WH, Hu RT, Huang CP, Hu KC, Chen CP, Lee CL, Chien RN, Chang KC, Hsu HY, Lee CC, Ni YH, Chang MH. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes. Liver Int. 2024 Jun;44(6):1422-1434.
  17. Chen HL. Management of chronic hepatitis B infection in children. Clin Liver Dis (Hoboken). 2024 Jun;23(1):e0156.
  18. Chen MF, Ho MC, Kao JH, Hwang RM, Deng SB, Yen KC, Liang PC, Wu CH. Comparison of CT and gadoxetic acid-enhanced MRI with liver imaging reporting and data system to assess liver tumors before resection. J Formos Med Assoc. 2024 Mar;123(3):318-324.
  19. Chen PJ. Challenges for hepatitis B control in Asia-Pacific areas: Consolidating vaccination and rolling-out antiviral therapies. J Gastroenterol Hepatol. 2024 Jun;39(6):1033-1039.
  20. Chen, CL, Tseng, TC, Liu, CJ, Kao, JH, Chen, PJ, Yang, WS Serum RNase L levels in patients with chronic hepatitis B virus infection. Hepatol Res. 2024 Mar,54(3):244-251.
  21. Cheng CL, Lin YY, Hsu CL, Li CL, Yuan CT, Lai YY, Fang WQ, Chen PJ, Yeh SH, Tien HF. Unraveling the role of hepatitis B virus DNA integration in B-cell lymphomagenesis. Br J Cancer. 2024 Oct;131(6):996-1004.
  22. Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease. J Formos Med Assoc. 2024 Jan;123(1):36-44.
  23. Cheng PN, Chen WJ, Hou CJ, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ. Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases. Clin Mol Hepatol. 2024 Jan;30(1):16-36.
  24. Cheng PN, Feng IC, Chen JJ, Kuo HT, Lee PL, Yu ML, Chiu YC, Chiu HC, Chien SC, Chen PJ, Liu CJ. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2024 Jan;59(2):230-238.
  25. Cheng PN, Liu CJ. Editorial: Tenofovir disoproxil fumarate more than an antiviral drug-Another piece of the puzzle. Authors' reply. Aliment Pharmacol Ther. 2024 Jan;59(2):289-290.
  26. Cheng YM, Wang SW, Wang CC, Kao JH. Clinical characteristics of lean metabolic- associated fatty liver disease and the impact of concurrent diabetes mellitus. Tzu Chi Med J. 2024 Jul 3;36(4):425-432
  27. Chua HH, Chen YH, Wu LL, Yang HC, Lin CR, Chen HL, Wu JF, Chang MH, Chen PJ, Ni YH. Antagonism between gut Ruminococcus gnavus and Akkermansia muciniphila modulates the progression of chronic hepatitis B. Cell Mol Gastroenterol Hepatol 2024; 17(3):361-81.
  28. Chung CY, Sun CP, Tao MH, Wu HL, Wang SH, Yeh SH, Zheng QB, Yuan Q, Xia NS, Ogawa K, Nakashima K, Suzuki T, Chen PJ. Major HBV splice variant encoding a novel protein important for infection. J Hepatol. 2024 Jun;80(6):858-867.
  29. Chung CY, Wang SH, Yeh SH, Chen PJ. Reply to: "Hepatitis B virus spliced 1 RNA, a key factor for viral expression". J Hepatol. 2025 Jan;82(1):e42-e43. 
  30. Fan SP, Chen YF, Li CH, Kuo YC, Lee NC, Chien YH, Hwu WL, Tseng TC, Su TH, Hsu CT, Chen HL, Lin CH, Ni YH. Topographical metal burden correlates with brain atrophy and clinical severity in Wilson's disease. Neuroimage. 2024 Oct 1;299:120829. 
  31. Hirode G, Hansen BE, Chen CH, Su TH, Wong GLH, Seto WK, d'Almeida AF, Papatheodoridi M, Brakenhoff SM, Lens S, Choi HSJ, Chien RN, Feld JJ, Forns X, Sonneveld MJ, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Chan HLY, Kao JH, Hsu YC, Cornberg M, Jeng WJ, Janssen HLA; RETRACT-B study group. Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). Am J Gastroenterol. 2024 Sep 1;119(9):1849-1856. 
  32. Ho CM, Lee PH, Cheng HY, Hsaio CY, Wu YM, Ho MC, Hu RH. Longitudinal analysis of liver transplant candidates for hepatocellular carcinoma in a single center. Langenbecks Arch Surg. 2024 Apr 29;409(1):143.
  33. Hou KC, Su TH, Kao CN, Cheng HR, Tseng TC, Liu CJ, Hsieh SC, Kao JH. Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B. J Gastroenterol Hepatol. 2024 Nov;39(11):2447-2455.
  34. Hsiao CY, Ho CM, Ho MC, Cheng HY, Wu YM, Lee PH, Hu RH. Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results. Surgery 2024 Jul;176(1):2-10
  35. Hsiao CY, Ho CM, Hu RH. Response letter to the editor—Original manuscript: Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results. Surgery 2024 Sep;176(3):978
  36. Huang JF, Chang TJ, Yeh ML, Shen FC, Tai CM, Chen JF, Huang YH, Hsu CY, Cheng PN, Lin CL, Hung CH, Chen CC, Lee MH, Lee CC, Lin CW, Liu SC, Yang HI, Chien RN, Kuo CS, Peng CY, Chang ML, Huang CF, Yang YS, Yang HC, Lin HC, Ou HY, Liu CJ, Tseng CH, Kao JH, Chuang WL, Huang CN, Chen PJ, Wang CY, Yu ML. Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus. Hepatol Commun. 2024 Oct 30;8(11):e0571
  37. Huang SC, Kao JH. The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review. Kaohsiung J Med Sci. 2024 Jan;40(1):6-10.
  38. Huang SC, Liu CJ, Kao JH. Impact of metabolic disorders on chronic hepatitis B. Clin Liver Dis (Hoboken). 2024 Apr 4;23(1):e0130.
  39. Huang SC, Su TH, Kao JH. Reply. Clin Gastroenterol Hepatol. 2024 Feb 5:S1542-3565(24)00106-X.
  40. Huang SC, Su TH, Kao JH. Response to the letter of HEPI-D-24-00252. Hepatology International. Hepatol Int. 2024 Aug;18(4):1340-1341.
  41. Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, Liao SH, Hong CM, Lan TY, Yang HC, Liu CJ, Chen PJ, Kao JH. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion. Clin Gastroenterol Hepatol. 2024 Mar,22(3):581-590.
  42. Huang SC, Su TH, Tseng TC, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. J Hepatol. 2024 Dec 13:S0168-8278(24)02763-6. 
  43. Huang YS, Hsieh SM, Tsai FC, Tung CC, Yang HC, Chang SY, Wang JT, Liu CJ, Su TH, Kao JH. Serological responses to COVID-19 vaccination in patients with chronic liver diseases. J Formos Med Assoc. 2024 Nov;123(11):1194-1197. 
  44. Huang YW, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, Abe H, Hu JT, Liu CJ, Lai MY, Chen DS, Yang SS, Kao JH. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antivir Ther. 2010;15(2):177-84.
  45. Inui A, Ko JS, Chongsrisawat V, Sibal A, Hardikar W, Chang MH, Treepongkaruna S, Arai K, Kim KM, Chen HL. Update on the diagnosis and management of neonatal intrahepatic cholestasis caused by citrin deficiency: Expert review on behalf of the Asian pan-pacific society for pediatric gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2024 Feb;78(2):178-87.
  46. Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Kuo HT, Yu ML. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry. J Formos Med Assoc. 2024 Aug 20:S0929-6646(24)00381-4.
  47. Janssen HL, Lim YS, Kim HJ, Sowah L, Tseng CH, Coffin CS, Elkhashab M, Ahn SH, Nguyen AH, Chen D, Wallin JJ, Fletcher SP, McDonald C, Yang JC, Gaggar A, Brainard DM, Fung S, Kim YJ, Kao JH, Chuang WL, Brooks AE, Dunbar PR. Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection. JHEP Rep. 2023 Nov 30;6(2):100975.
  48. KC Chang, TH Su, SH Liao, TC Tseng, SC Huang, SJ Hsu, CM Hong, CH Liu, HC Yang, CJ Liu, JH Kao. Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy. J Formos Med Assoc. 2024 Feb 28:S0929-6646(24)00111-6.
  49. Kor-Anantakul P, Chen HL, Chen YH, Ittiwut C, Ittiwut R, Chaijitraruch N, Suphapeetiporn K, Chongsrisawat V. Novel PLEC variants associated with infantile cholestasis. Clin Genet. 2024 Dec;106(6):769-75.
  50. Kuo TC, Wu CH, Chen BB, Lin YJ, Ho CM, Tseng CK, Cheng YM, Tien YW. Most total pancreatectomies for ductal adenocarcinoma can be replaced by whipple over the splenic artery: a before and after study. Int J Surg . 2024 Oct 1;110(10):6461-6469.
  51. Lai SK, Luo AC, Chiu IH, Chuang HW, Chou TH, Hung TK, Hsu JS, Chen CY, Yang WS, Yang YC, Chen PL. A novel framework for human leukocyte antigen (HLA) genotyping using probe capture-based targeted next-generation sequencing and computational analysis. Comput Struct Biotechnol J. 2024 Apr 2;23:1562-1571. 
  52. Lai SL, Chang CH, Lee PC, Ho CM, Wu JM, Lai HS, Lin BR. Impact of preoperative factors and waiting time on post-appendectomy complications: a retrospective study. Perioper Med (Lond). 2024 Feb 21;13(1):8.
  53. Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, Otsuka M, Ogasawara S, George J,  Chow PKH, Cai J, Shiina S, Kato N, Yokosuka O, Oura K, Yau T, Chan SL, Kuang M, Ueno Y, Chen M, Cheng AL, Cheng G, Chuang WL, Baatarkhuu O, Bi F, Dan YY, Gani RA, Tanaka A, Jafri W, Jia JD, Kao JH, Hasegawa K, Lau P, Lee JM, Liang J, Liu Z, Lu Y, Pan H, Payawal DA, Rahman S, Seong J, Shen F, Shiha G, Song T, Sun HC, Masaki T, Sirachainan E, Wei L, Yang JM, Sallano JD, Zhang Y, Tanwandee T, Dokmeci A, Zheng SS, Fan J, Fan ST, Sarin SK, Omata M. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatol Int. 2024 Dec;18(6):1661-1683.
  54. Lee CS, Lin CR, Chua HH, Wu JF, Chang KC, Ni YH, Chang MH, Chen HL. Corrigendum to: 'Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia' (JHEP Reports, Volume 6, Issue 7, July 2024, 101090). JHEP Rep. 2024 Nov 20;6(12):101253.
  55. Lee CS, Lin CR, Chua HH, Wu JF, Chang KC, Ni YH, Chang MH, Chen HL. Gut Bifidobacterium longum is associated with better native liver survival in patients with biliary atresia. JHEP Rep. 2024 Apr 9;6(7):101090.
  56. Lee JW, Tai CS, Chang KC, Chiu YC, Ni YH, Wu JF. The benefits of transnasal endoscopy compared to conventional endoscopy in adolescents. J Formos Med Assoc. 2024 Nov 9:S0929-6646(24)00542-4.
  57. Li CL, Hsu CL, Lin YY, Ho MC, Hu RH, Chen CL, Ho TC, Lin YF, Tsai SF, Tzeng ST, Huang CF, Wang YC, Yeh SH, Chen PJ. HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-Related HCC with Distinct Features. Liver Cancer. 2023 Apr 17;13(1):41-55.
  58. Liao YT, Huang J, Hung JS, Huang KW, Liang JT. Staging Paradox and recurrence pattern among stage IIB, IIC, and IIIA Colon cancers: a retrospective cohort study. Int J Colorectal Dis. 2024 Oct 14;39(1):161.
  59. Lin CL, Kao JH. Should we expand treatment initiation criteria for chronic HBV infection: Pros. Clin Liver Dis (Hoboken). 2024 Jun 12;23(1):e0228.
  60. Lin MJ, Su TH, Kao JH. Reply to "Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy". J Formos Med Assoc. 2024 Feb;123(2):297-298.
  61. Lin TY, Su TH. Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma-report a case and literature review J Formos Med Assoc. 2024 Aug;123(8):916-919. 
  62. Liu CH, Chang YP, Fang YJ, Cheng PN, Chen CY, Kao WY, Lin CL, Yang SS , Shih YL, Peng CY, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals. J Gastroenterol. 2024 Jul,59(7):609-620.
  63. Liu CH, Chang YP, Kao JH. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review. Expert Opin Pharmacother. 2024 Aug;25(12):1691-1706.
  64. Liu CH, Chang YP, Lee JY, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals. J Med Virol. 2024 May;96(5):e29675.
  65. Liu CJ, Seto WK, Yu ML. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD. Hepatol Int. 2024 Oct;18(Suppl 2):897-908.
  66. Lu CW, Wu CH, Huang MT, Lee CS, Chen HL, Lin MT, Chiu SN, Tseng WC, Chen CA, Wang JK, Wu MH. Liver fibrosis detected by diffusion-weighted magnetic resonance imaging and its functional correlates in Fontan patients. Eur J Cardiothorac Surg. 2024 Jul;66(1):ezae249.
  67. Lu MY, Huang CF, Hung CH, Tai CM, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML; TACR Study Group. Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program. Clin Mol Hepatol. 2024 Jan;30(1):64-79.
  68. Pan Z, Seto WK, Liu CJ, Mao Y, Alqahtani SA, Eslam M. A literature review of genetics and epigenetics of HCV-related hepatocellular carcinoma: translational impact. Hepatobiliary Surg Nutr. 2024 Aug 1;13(4):650-661.
  69. Panyod S, Wu WK, Hsieh YC, Tseng YJ, Peng SY, Chen RA, Huang HS, Chen YH, Shen TD, Ho CT, Liu CJ, Chuang HL, Huang CC, Wu MS, Sheen LY. Ginger essential oil prevents NASH progression by blocking the NLRP3 inflammasome and remodeling the gut microbiota-LPS-TLR4 pathway in mice. Nutr Diabetes. 2024 Aug 16;14(1):65. 
  70. Panyod S, Wu WK, Hu MY, Huang HS, Chen RA, Chen YH, Shen TCD, Ho CT, Liu CJ, Chuang HL, Huang CC, Wu MS, Sheen LY. Healthy diet intervention reverses the progression of NASH through gut microbiota modulation. Microbiol Spectr. 2024 Jan 11;12(1):e0186823.
  71. Peng YC, Liao SH, Tsai JH, Chen PT, Chang CC, Kao JH, Liu KL. Comparison of the clinicoradiological features and outcomes of lymphoepithelioma-like cholangiocarcinoma and conventional intrahepatic cholangiocarcinoma: A propensity score matching analysis. J Formos Med Assoc. 2024 Aug 14:S0929-6646(24)00379-6. 
  72. Pradita T, Chen YJ, Su TH, Chang KH, Chen PJ, Chen YJ. Data Independent Acquisition Mass Spectrometry Enhanced Personalized Glycosylation Profiling of Haptoglobin in Hepatocellular Carcinoma. J Proteome Res. 2024 Aug 2;23(8):3571-3584. 
  73. Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, Li CL, Wei F, Xu Y, Imai K, Takai K, Chuma M, Komatsu N, Furutani Y, Gailhouste L, Aikata H, Chayama K, Enomoto M, Tateishi R, Kawaguchi K, Yamashita T, Kaneko S, Nagaoka K, Tanaka M, Sasaki Y, Tanaka Y, Baba H, Miura K, Ochi S, Masaki T, Kojima S, Matsuura T, Shimizu M, Chen PJ, Moriwaki H, Suzuki H. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. Int J Cancer. 2024 Aug 1;155(3):582-594.
  74. Su PA, Chang CH, Yen SB, Wu HY, Tung WJ, Hu YP, Chen YI, Lin MH, Shih C, Chen PJ, Tsai K. Epitranscriptomic cytidine methylation of the hepatitis B viral RNA is essential for viral reverse transcription and particle production. Proc Natl Acad Sci U S A. 2024 Jun 11;121(24):e2400378121.
  75. Su TH, Kao JH. Reply to comment on "Pre-operative gamma-glutamyl transferase levels predict outcomes in hepatitis B-related hepatocellular carcinoma after curative resection". J Formos Med Assoc. 123(6):725-726.
  76. Su TH, Kao JH. Role of artificial intelligence in the management of chronic hepatitis B infection. Clin Liver Dis (Hoboken). 2024 May 3;23(1):e0164.
  77. Su WJ, Chen HL, Chen SF, Liu YL, Wang TA, Ho YC, Chang MH. Optimization of Mother-to-Child Hepatitis B Virus Prevention Program: Integration of Maternal Screening and Infant Post-Vaccination Serologic Testing. Clin Infect Dis. 2024 Sep 26;79(3):690-700.
  78. Tsai H, Yang TW, Ou KH, Su TH, Lin C, Chou CF. Multimodal Attention Network for Dementia Prediction. IEEE J Biomed Health Inform. 2024 Nov;28(11):6918-6930. 
  79. Tsai PC, Huang CF, Yeh ML, Hsieh MH, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Chen CY, Huang JF, Dai CY, Chung WL, Bair MJ, Yu ML; T-COACH Study Group. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy. Clin Mol Hepatol. 2024 Jul;30(3):468-486.
  80. Tseng TC, Cheng HR, Su TH, Lin PH, Wang CC, Yang HC, Tsai CS, Liu CJ, Chen PJ, Kao JH. Higher hepatitis B core-specific T cell response is associated with a lower risk of clinical relapse after discontinuation of oral antiviral treatment. J Microbiol Immunol Infect. 2024 Oct;57(5):700-708.
  81. Wang CC, Cheng YM, Kao JH. Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization. Hepatology. 2024 Jan 1;79(1):E7-E8.
  82. Wu HY, Su TH, Liu CJ, Yang HC, Tsai JH, Wei MH, Chen CC, Tung CC, Kao JH, Chen PJ.  Hepatitis B reactivation: A possible cause of coronavirus disease 2019 vaccine induced hepatitis. J Formos Med Assoc. 2024 Jan;123(1):88-97.
  83. Wu JF, Peng SS, Tai CS, Lin WH, Jeng YM, Hsu WM, Chen HL, Ni YH, Chang MH. The magnetic resonance imaging and age-adjusted matrix metalloproteinase-7 assist the diagnosis of biliary atresia. J Gastroenterol 2024; 59(2):138-44.
  84. Wu JF, Tai CS, Chang KC, Chen TW, Chen HL, Ni YH, Hsu HY, Chang MH. CTLA-4 haplotype predicts HBsAg and HBcrAg levels and HBeAg seroconversion age in children with chronic HBV infection. JHEP Rep 2024 Mar 8;6(5):101061.
  85. Wu JF, Tai CS, Chang KC, Chen YJ, Hsu CT, Chen HL, Ni YH, Chang MH. Predictors of functional cure of chronic hepatitis B virus infection - A long-term follow-up study. Clin Gastroenterol Hepatol. 2024 Aug 28:S1542-3565(24)00774-2.
  86. Wu JF, Yen HH, Wang HY, Chang TA, Chang CH, Chang CW, Chao TH, Chou JW, Chou YH, Chuang CH, Hsu WH, Hsu TC, Huang TY, Hung TI, Le PH, Lin CC, Lin CC, Lin CP, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsai TJ, Wang CY, Weng MT, Wong JM, Wu DC, Wei SC. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023. Intest Res. 2024 Jul;22(3):250-285.
  87. Wu NM, Chiang C, Lin KP, Chen YM, Yang WS. Muscle strength in ostensibly healthy non-diabetic subjects. J Formos Med Assoc. 2024 Jun;123(6):664-670.
  88. Xu M, Warner C, Duan X, Cheng Z, Jeyarajan AJ, Li W, Wang Y, Shao T, Salloum S, Chen PJ, Yu X, Chung RT, Lin W. HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1α- and TGF-β1-dependent pathway. J Hepatol. 2024 Jun;80(6):868-881. 
  89. Yang CC, Huang CF, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Kuo HT, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Yu ML. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naive Patients from a Nationwide HCV Registry in Taiwan. Infect Dis Ther. 2024 Jun;13(6):1199-1213.
  90. Yang TK, Wang YJ, Li HJ, Yu YF, Huang KW, Cheng JC. Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis: A Systematic Review and Meta-Analysis. J Clin Med. 2024 Aug 12;13(16):4724. 
  91. Yen HH, Wu JF, Wang HY, Chang TA, Chang CH, Chang CW, Chao TH, Chou JW, Chou YH, Chuang CH, Hsu WH, Hsu TC, Huang TY, Hung TI, Le PH, Lin CC, Lin CC, Lin CP, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsai TJ, Wang CY, Weng MT, Wong JM, Wu DC, Wei SC. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023. Intest Res. 2024 Jul;22(3):213-249.
  92. Younossi ZM, Alqahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome PN, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Fornaresio L, Nader F, Henry L, Racila A, Golabi P, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024 Mar;80(3):419-430.
  93. YP Chang, CB Huang, TH Su, CJ Liu, TC Tseng, SC Huang, PJ Chen, JH Kao, CH Liu. Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping. J Med Virol. 2024 May;96(5):e29686.
  94. Yu ML, Tai CM, Mo LR, Kuo HT, Huang CF, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Hung CH, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Chen CY, Kao JH, Lin HC, Chuang WL, Peng CY. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan. Hepatol Int. 2024 Apr;18(2):461-475
  95. Zhang H, Targher G, Byrne CD, Kim SU, Wong VW, Valenti L, Glickman M, Ponce J, Mantzoros CS, Crespo J, Gronbaek H, Yang W, Eslam M, Wong RJ, Machado MV, Yu ML, Ghanem OM, Okanoue T, Liu JF, Lee YH, Xu XY, Pan Q, Sui M, Lonardo A, Yilmaz Y, Zhu LY, Moreno C, Miele L, Lupsor-Platon M, Zhao L, LaMasters TL, Gish RG, Zhang H, Nedelcu M, Chan WK, Xia MF, Bril F, Shi JP, Datz C, Romeo S, Sun J, Liu D, Sookoian S, Mao YM, Méndez-Sánchez N, Wang XY, Pyrsopoulos NT, Fan JG, Fouad Y, Sun DQ, Giannini C, Chai J, Xia ZF, Jun DW, Li GJ, Treeprasertsuk S, Li YX, Cheung TT, Zhang F, Goh GB, Furuhashi M, Seto WK, Huang H, Di Sessa A, Li QH, Cholongitas E, Zhang L, Silveira TR, Sebastiani G, Adams LA, Chen W, Qi X, Rankovic I, De Ledinghen V, Lv WJ, Hamaguchi M, Kassir R, Müller-Wieland D, Romero-Gomez M, Xu Y, Xu YC, Chen SY, Kermansaravi M, Kuchay MS, Lefere S, Parmar C, Lip GYH, Liu CJ, Åberg F, Lau G, George J, Sarin SK, Zhou JY, Zheng MH; MAFLD ICD-11 coding collaborators. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2024 Aug;18(4):1178-1201.
  96. Zoulim F, Chen PJ, Dandri M, Kennedy PT, Seeger C. Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome. J Hepatol. 2024 Dec;81(6):1087-1099.

新聞亮點

新聞報紙